Royalty Pharma PLC - Class A (RPRX) closed at $63.75 on October 22, 2026, up 2.6% from the previous close, on volume of 2,634,070 shares (30-day average 2,931,464).
Data as of October 22, 2026.
Goldman's defensive stocks with quality-growth characteristics
Seeking Alpha News (Sun, 18-Oct 11:04 AM ET)
Royalty Pharma declares fourth quarter 2026 dividend
Globe Newswire (Fri, 16-Oct 8:00 AM ET)
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Globe Newswire (Fri, 9-Oct 8:50 AM ET)
Globe Newswire (Tue, 15-Sep 4:35 PM ET)
Royalty Pharma to present at upcoming investor conferences
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Globe Newswire (Fri, 4-Sep 7:05 PM ET)
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Globe Newswire (Wed, 12-Aug 4:10 PM ET)
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Royalty Pharma Raises 2026 Guidance After Double-Digit Growth Across Key Royalty Streams
Market Chameleon (Wed, 5-Aug 5:48 AM ET)
Royalty Pharma reports second quarter 2026 results
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.
As of October 22, 2026, RPRX stock price climbed to $63.75 with 2,634,070 million shares trading.
RPRX has a beta of 0.01, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.00 to the broad based SPY ETF.
RPRX has a market cap of $28.39 billion. This is considered a Large Cap stock.
Last quarter Royalty Pharma PLC - Class A reported $674 million in Revenue and $1.32 earnings per share. This fell short of revenue expectation by $-121 million and exceeded earnings estimates by $.05.
In the last 3 years, RPRX traded as high as $64.38 and as low as $24.05.
The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, IWR, VYM, CGDG.
RPRX has outperformed the market in the last year with a price return of +72.6% while the SPY ETF gained +14.9%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.5% and +12.3%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
RPRX support price is $61.21 and resistance is $63.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.
